Stoking the drug target pipeline for human African trypanosomiasis

Molecular Microbiology

Volumn 86, Issue 1, 2012, Pages 10-14

  Phillips, Margaret A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITRYPANOSOMAL AGENT; DIHYDROOROTATE DEHYDROGENASE; EFLORNITHINE; FEXINIDAZOLE; MELARSOPROL; NIFURTIMOX; OXABOROLE; PENTAMIDINE; PYRIDOXAL KINASE; SCYX 7158; SURAMIN; UNCLASSIFIED DRUG;

AFRICAN TRYPANOSOMIASIS; CLINICAL EFFECTIVENESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; GENE SILENCING; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; NOTE; OUTCOME ASSESSMENT; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TRYPANOSOMA BRUCEI; UNSPECIFIED SIDE EFFECT;

ANIMALS; HUMANS; PYRIDOXAL KINASE; TRYPANOSOMA BRUCEI BRUCEI;

TRYPANOSOMA BRUCEI;

EID: 84867096012     PISSN: 0950382X     EISSN: 13652958     Source Type: Journal    
DOI: 10.1111/mmi.12001     Document Type: Note

References (34)

1. Aguero, F., Al-Lazikani, B., Aslett, M., Berriman, M., Buckner, F.S., Campbell, R.K., etal. (2008) Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov 7: 900-907.
2. Alsford, S., Turner, D.J., Obado, S.O., Sanchez-Flores, A., Glover, L., Berriman, M., etal. (2011) High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome. Genome Res 21: 915-924.
3. Alsford, S., Eckert, S., Baker, N., Glover, L., Sanchez-Flores, A., Leung, K.F., etal. (2012) High-throughput decoding of antitrypanosomal drug efficacy and resistance. Nature 482: 232-236.
4. Barrett, M.P. (2010) Potential new drugs for human African trypanosomiasis: some progress at last. Curr Opin Infect Dis 23: 603-608.
5. Barrett, M.P., Boykin, D.W., Brun, R., and Tidwell, R.R. (2007) Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br J Pharmacol 152: 1155-1171.
6. Berriman, M., Ghedin, E., Hertz-Fowler, C., Blandin, G., Renauld, H., Bartholomeu, D.C., etal. (2005) The genome of the African trypanosome Trypanosoma brucei. Science 309: 416-422.
7. Brun, R., Blum, J., Chappuis, F., and Burri, C. (2010) Human African trypanosomiasis. Lancet 375: 148-159.
8. Brun, R., Don, R., Jacobs, R.T., Wang, M.Z., and Barrett, M. (2011) Development of novel drugs for human African trypanosomiasis. Future Microbiol 6: 677-691.
9. Burri, C. (2010) Chemotherapy against human African trypanosomiasis: is there a road to success? Parasitology 137: 1987-1994.
10. Burrows, J.N., Chibale, K., and Wells, T.N. (2011a) The state of the art in anti-malarial drug discovery and development. Curr Top Med Chem 11: 1226-1254.
11. Burrows, J.N., Leroy, D., Lotharius, J., and Waterson, D. (2011b) Challenges in antimalarial drug discovery. Future Med Chem 3: 1401-1412.
12. Chatelain, E., and Ioset, J.R. (2011) Drug discovery and development for neglected diseases: the DNDi model. Drug Des Dev Ther 5: 175-181.
13. Chatterjee, A.K., and Yeung, B.K. (2012) Back to the future: lessons learned in modern target-based and whole-cell lead optimization of antimalarials. Curr Top Med Chem 12: 473-483.
14. Coteron, J.M., Marco, M., Esquivias, J., Deng, X., White, K.L., White, J., etal. (2011) Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. J Med Chem 54: 5540-5561.
15. Hall, B.S., Bot, C., and Wilkinson, S.R. (2011) Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J Biol Chem 286: 13088-13095.
16. Jacobs, R.T., Nare, B., and Phillips, M.A. (2011a) State of the art in African trypanosome drug discovery. Curr Top Med Chem 11: 1255-1274.
17. Jacobs, R.T., Nare, B., Wring, S.A., Orr, M.D., Chen, D., Sligar, J.M., etal. (2011b) SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis 5: e1151.
18. Jones, D.C., Alphey, M.S., Wyllie, S., and Fairlamb, A.H. (2012) Chemical, genetic and structural assessment of pyridoxal kinase as a drug target in the African trypanosome. Mol Microbiol 86: 51-64..
19. Kaiser, M., Bray, M.A., Cal, M., Bourdin Trunz, B., Torreele, E., and Brun, R. (2011) Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob Agents Chemother 55: 5602-5608.
20. Kennedy, P.G. (2008) The continuing problem of human African trypanosomiasis (sleeping sickness). Ann Neurol 64: 116-126.
21. Kolev, N.G., Tschudi, C., and Ullu, E. (2011) RNA interference in protozoan parasites: achievements and challenges. Eukaryot Cell 10: 1156-1163.
22. Lanteri, C.A., Tidwell, R.R., and Meshnick, S.R. (2008) The mitochondrion is a site of trypanocidal action of the aromatic diamidine DB75 in bloodstream forms of Trypanosoma brucei. Antimicrob Agents Chemother 52: 875-882.
23. MacGregor, P., Szoor, B., Savill, N.J., and Matthews, K.R. (2012) Trypanosomal immune evasion, chronicity and transmission: an elegant balancing act. Nat Rev Microbiol 10: 431-438.
24. Magarinos, M.P., Carmona, S.J., Crowther, G.J., Ralph, S.A., Roos, D.S., Shanmugam, D., etal. (2012) TDR Targets: a chemogenomics resource for neglected diseases. Nucleic Acids Res 40: D1118-D1127.
25. Maser, P., Wittlin, S., Rottmann, M., Wenzler, T., Kaiser, M., and Brun, R. (2012) Antiparasitic agents: new drugs on the horizon. Curr Opin Pharmacol http://dx.doi.org/10.1016/j.bbr.2011.03.031.
26. Morgan, H.P., McNae, I.W., Nowicki, M.W., Zhong, W., Michels, P.A., Auld, D.S., etal. (2011) The trypanocidal drug suramin and other trypan blue mimetics are inhibitors of pyruvate kinases and bind to the adenosine site. J Biol Chem 286: 31232-31240.
27. Phillips, M.A., and Rathod, P.K. (2010) Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy. Infect Disord Drug Targets 10: 226-239.
28. Siegel, T.N., Gunasekera, K., Cross, G.A., and Ochsenreiter, T. (2011) Gene expression in Trypanosoma brucei: lessons from high-throughput RNA sequencing. Trends Parasitol 27: 434-441.
29. Stuart, K., Brun, R., Croft, S., Fairlamb, A., Gurtler, R.E., McKerrow, J., etal. (2008) Kinetoplastids: related protozoan pathogens, different diseases. J Clin Invest 118: 1301-1310.
30. Wastling, S.L., and Welburn, S.C. (2011) Diagnosis of human sleeping sickness: sense and sensitivity. Trends Parasitol 27: 394-402.
31. Wilkinson, S.R., Taylor, M.C., Horn, D., Kelly, J.M., and Cheeseman, I. (2008) A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci USA 105: 5022-5027.
32. Wirtz, E., Leal, S., Ochatt, C., and Cross, G.A. (1999) A tightly regulated inducible expression system for conditional gene knock-outs and dominant-negative genetics in Trypanosoma brucei. Mol Biochem Parasitol 99: 89-101.
33. Wyllie, S., Patterson, S., Stojanovski, L., Simeons, F.R., Norval, S., Kime, R., etal. (2012) The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis. Sci Transl Med 4: 119re111.
34. Yun, O., Priotto, G., Tong, J., Flevaud, L., and Chappuis, F. (2010) NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis 4: e720.